18-Methylaminocoronaridine

Chemical compound 477189939 18-Methylaminocoronaridine.svg skin-invert-image 225px 18-MAC 3D.png bg-transparent 200px 1807784-35-5 changed EPA 71308131 correct chemspider 24721797 22 29 3 2 c4cccc1c4[nH]c3c1CCN2CC(C5)CC3(C(=O)OC)C2C5CCNC correct chemspider 1S/C22H29N3O2/c1-23-9-7-15-11-14-12-22(21(26)27-2)19-17(8-10-25(13-14)20(15)22)16-5-3-4-6-18(16)24-19/h3-6,14-15,20,23-24H,7-13H2,1-2H3/t14-,15+,20+,22-/m1/s1 correct chemspider YKMOJVPLIUXEIP-SVBQBFEESA-N (−)-18-Methylaminocoronaridine (18-MAC) is a second generation synthetic derivative of ibogaine developed by the research team led by the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont. Kuehne ME, He L, Jokiel PA, Pace CJ, Fleck MW, Maisonneuve IM, Glick SD, Bidlack JM 6 Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents Journal of Medicinal Chemistry 46 13 2716–30 June 2003 12801235 10.1021/jm020562o Pace CJ, Glick SD, Maisonneuve IM, He LW, Jokiel PA, Kuehne ME, Fleck MW Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration European Journal of Pharmacology 492 2–3 159–67 May 2004 15178360 10.1016/j.ejphar.2004.03.062 See also 2-Methoxyethyl-18-methoxycoronaridinate 18-Methoxycoronaridine Coronaridine Ibogaine Noribogaine Voacangine References Category:Anti-addictive drugs Category:Drug rehabilitation Category:Tabernanthe iboga Category:Nicotinic antagonists